Friday, 17 Aug 2018

You are here

EMA to Review Methotrexate Overdose and Dosing Errors

A recent meeting (April 9-12) of the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) considered the problem of dosing errors with methotrexate (MTX), citing "continued reports of overdose." 

Although usually dosed at low doses,  given weekly (for rheumatoid arthritis; higher in some malignancies), the EMA has noted reports of improper MTX dosing that has lead to fatal or serious outcomes in some reports. Prompted by the Spanish medicines regulator, AEMPS, the PRAC was asked to investigate why dosing errors continue with MTX.  

There has been sporadic reports of MTX dosing errors for years, but the EMA notes that measures to reduce this risk are unclear.

Medscape reports that the PRAC will examine the evidence and make recommendations to the Committee for Medicinal Products for Human Use, on how to minimize this risk. (Citation souce:  https://wb.md/2H2Et46)

Severe toxicity from MTX may include mucosal or gastrointestinal tract ulceration, liver toxicity, bone marrow suppression, septicemia, or death.  Risk factors for MTX overdose/toxicity typically include renal insufficiency (or sudden decline in renal function), hypoalbuminemia, dosing errors (use of higher than recommended doses) and failure to use folate supplementation.

Several recent reports underscore the serious consequences of rarely seen MTX dosing errors. 

  • Ajmani et al reported on 46 cases of MTX induced severe pancytopenia observed over a 19 year period. They noted a high mortality rate (13/46) and that the presenting symptoms may be high fever and severe mucositis. Common features included: oral mucositis (n = 37); fever (24); diarrhea (12), bleeding gums (5) and purpura (3). http://bit.ly/2JLjXa5 
  • A study of 4 different Danish registers identified 173 errors with nearly two-thirds resulting in harm. Serious harm occurred in 15% and there were 9 deaths (5%). These involved involved incorrect daily administration (31%), dosing errors (62%) and 9% had improper \monitoring. Prescription errors involving daily rather than weekly administration, by hospital physicians, were most likely to result in serious outcomes, including deaths. http://bit.ly/2JLlxZz
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).